Trial Profile
Comprehensive analysis to identify transcriptomic signatures that positively or negatively correlate with clinical outcome of nivolumab monotherapy in patients with non-small cell lung carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms CTSN study
- 24 May 2018 Status changed from not yet recruiting to recruiting.
- 25 Apr 2017 New trial record